GenSight Biologics is set to present new data on LUMEVOQ®, their gene therapy for LHON, at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society.

The company will share evidence of LUMEVOQ®'s efficacy, including success in transfecting retinal ganglion cells, improving visual acuity, and offering better visual recovery than other treatments.

Analyses will highlight LUMEVOQ®'s impact on patients' quality of life and compare its effectiveness with natural LHON progression and idebenone treatment.

The European Medicines Agency has recognized LUMEVOQ® as the invented name for GenSight's lead product candidate GS010, which is currently in Phase III trials.

GS010 targets Leber's Hereditary Optic Neuropathy (LHON), a rare genetic disorder causing blindness, with a focus on teens and young adults.

For additional information, inquiries can be directed to GenSight's CFO Ivan Tortet or LifeSci Advisors' Investor Relations representative Guillaume van Renterghem.